Company: PMVP
Filing Date: 2025-03-03
Form Type: 10-K
Source: 0000950170-25-030414
Chunk: 209

Company: PMV Pharmaceuticals, Inc.
Filing Date: 2025-03-03
Form: 10-K
Item: Item 7
Chunk 209
---
 and premiums on marketable securities.

 93

Results of Operations

Comparison of the Years Ended December 31, 2024 and 2023

The following table summarizes our results of operations (in thousands):

    Year Ended

    December 31,

    Statement of operations data:
     
    2024

    2023

    Change

    Operating expenses:

    Research and development
     
    $
    58,527

    $
    55,885

    $
    2,642

    General and administrative

    26,921

    24,247

    2,674

    Total operating expenses

    85,448

    80,132

    5,316

    Loss from operations

    (85,448
    )

    (80,132
    )

    (5,316
    )

    Other income (expense):

    Interest income, net

    10,655

    11,171

    (516
    )

    Other income (expense), net

    (16
    )

    3

    (19
    )

    Total other income (expense)

    10,639

    11,174

    (535
    )

    Loss before provision (benefit) for income taxes

    (74,809
    )

    (68,958
    )

    (5,851
    )

    Provision (benefit) for income taxes

    (16,100
    )

    2

    (16,102
    )

    Net loss
     
    $
    (58,709
    )
     
    $
    (68,960
    )
     
    $
    10,251

Research and Development Expenses

The following table summarizes our research and development expenses incurred during the periods indicated (in thousands):

    Year Ended

    December 31,

    Statement of operations data:
     
    2024

    2023
     
    Change

    Research
     
    $
    5,914

    $
    5,307
     
    $
    607

    Development

    35,295

    31,740

    3,555

    Personnel related

    13,662

    13,320

    342

    Stock-based compensation

    3,656

    5,518

    (1,